Patents Examined by Michael G. Hartley
  • Patent number: 10201625
    Abstract: Novel radiotracer(s) for Positron Emission Tomography (PET) imaging are described. Novel radiotracer(s) for Positron Emission Tomography (PET) imaging of neuorendocrine tumors are described. Specifically the present invention describes novel [18F]Fluoroethyltriazol-[Tyr3]Octreotate analogs; in particular those that target somatostatin receptors found on the cell surface of gastroenteropancreatic neuorendocrine tumors. The present invention also describes intermediate(s), precursor(s), pharmaceutical composition(s), methods of making, and methods of use of the novel radiotracer(s).
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: February 12, 2019
    Assignees: IMPERIAL COLLEGE, GE HEALTHCARE LIMITED
    Inventors: Sajinker Kaur Luthra, Julius Leyton, Eric Ofori Aboagye, Lisa Iddon, Bard Indrevoll, Matthias Eberhard Glaser, Alan Cuthbertson
  • Patent number: 10201623
    Abstract: The present invention provides new methods for cardiac imaging and related medical applications thereof. In some embodiments, the present invention provides a method for the diagnosis of cardiovascular diseases, conditions, or disorders. In some embodiments, the present invention provides a method for the treatment or prevention of cardiovascular diseases, conditions, or disorders. In some embodiments, the present invention provides methods for monitoring the effect of cancer treatment on the heart, and/or methods for monitoring a cancer treatment regimen. In some embodiments, the present invention provides a method for selecting subjects for a test or treatment. In some embodiments, the present invention provides a method for determining the dosage of a drug. In some embodiments, the present invention provides methods for determining the risk of a cardiovascular disease, for assessing risk of a cardiovascular disease, and/or for determining the risk of heart attack.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 12, 2019
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Mark Dunphy, H. William Strauss, Gabriela Chiosis
  • Patent number: 10202342
    Abstract: The present invention relates to nitroxide imaging probes that are isotopically modified or unmodified. Such nitroxide imaging probes may be included in liposomes that encapsulate self-quenching concentrations thereof, wherein the liposomes optionally comprise a targeting ligand specific to and having affinity for targeted tissue.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: February 12, 2019
    Assignee: University of Maryland, Baltimore
    Inventors: Joseph P. Y. Kao, Scott R. Burks, Gerald R. Rosen
  • Patent number: 10196412
    Abstract: Provided are embodiments of a small molecule tracer for positron emission tomography (PET) imaging of the enzyme activity of PARP-1 that is responsible for DNA-damage sensing and critically involved in radiation therapy and some chemotherapy response mechanisms. These PARP-1 tracers are derivatives of nicotinamide adenine dinucleotide (NAD), which is the natural substrate for PARP-1. Provided are NAD derivatives that include a linker moiety to which may be attached a label moiety such as a PET detectable fluorine to generate a 6N-(triazo-PEG2-18F)-NAD. Especially advantageous for use in PET and MRI scanning detection systems is the attachment of a chelating agent that allows for the formation of a chelator-metal ion complex.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 5, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Adam Shuhendler, Lina Cui, Jianghong Rao
  • Patent number: 10195127
    Abstract: The present invention provides a cosmetic composition containing (A) a powder composed of one or more kinds of the N-medium-chain-acyl basic amino acid powder represented by the following formula (I), (B) an inorganic powder, and (C) an oil material: wherein R is a saturated or unsaturated straight hydrocarbon group having 5-9 carbon atoms, and m is an integer of 1-4.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: February 5, 2019
    Assignee: AJINOMOTO CO., INC.
    Inventors: Masayuki Kuramoto, Eiko Oshimura
  • Patent number: 10195295
    Abstract: A process for purifying a compound of formula 1, includes the following steps: a) adding an acid to an aqueous solution of the compound of formula 1, including salts and hydrates thereof so as to obtain a slurry having a pH?3; and b) filtering the slurry and at least one time washing the obtained precipitate with a liquid comprising water; and c) dissolving the precipitate obtained in step b) in water to obtain an aqueous solution; and d) filtering of the solution obtained in step c) over a nanofiltration membrane having a Molecular Weight Cut Off in the range from 150 to 500 and wherein optionally, between step c) and step d) the pH of the aqueous solution is adjusted to a pH value in the pH range as specified by the manufacturer of the nanofiltration membrane. A process for preparing a gadolinium complex of the purified compound of formula 1 is also disclosed. This gadolinium complex can be used for making a pharmaceutical composition as a contrast agent for magnetic resonance imaging.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: February 5, 2019
    Assignee: T2PHARMA GMBH
    Inventors: Diederik Buffel, Xavier Boi, Judith Pype
  • Patent number: 10195296
    Abstract: The present invention provides contrast agents for photoacoustic imaging which exhibit high degrees of accumulation in tumor and low degrees of retention in the blood and can be administered into the blood. The contrast agents for photoacoustic imaging include a conjugate of a dye and a polyethyleneglycol represented by Formula (1), (5), (6), or (7) and an additive represented by Formula (301).
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: February 5, 2019
    Assignee: CANON KABUSHIKI KAISHA
    Inventors: Tatsuki Fukui, Atsushi Takahashi, Daisuke Sasaguri, Kouichi Kato, Fumiko Tomatsu, Keigo Mizusawa
  • Patent number: 10199130
    Abstract: Methods for isolating Pb and/or Pb isotopes from various sources are provided. Compositions comprising Pb and/or Pb isotopes free of certain amounts of various contaminants are also provided.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: February 5, 2019
    Assignee: Lantheus Medical Imaging, Inc.
    Inventor: Keith R. Olewine
  • Patent number: 10188756
    Abstract: Disclosed herein are histone deacetylase imaging agents for positron emission tomography and related imaging methods using the histone deacetylase imaging agents. The histone deacetylase imaging agents may be a compound of formula (I): wherein R1 is a moiety including a positron emitter; R2 represents hydrogen, or substituted or unsubstituted alkyl, or substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and n is an integer selected from 0 or 1. In one version of the compound of formula (I), R1 is a moiety including an adamantyl group.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: January 29, 2019
    Assignee: The General Hospital Corporation
    Inventors: Jacob M. Hooker, Changning Wang, Frederick Albert Schroeder
  • Patent number: 10188755
    Abstract: The present invention relates to a magnetic resonance structure with a cavity or a reserved space that provides contrast and the additional ability to frequency-shift the spectral signature of the NMR-susceptible nuclei such as water protons by a discrete and controllable characteristic frequency shift that is unique to each MRS design. The invention also relates to nearly uniform solid magnetic resonance T2* contrast agents that have a significantly higher magnetic moment compared to similarly-sized existing MRI contrast agents.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: January 29, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The United States of America, as represented by the Secretary of Commerce
    Inventors: Gary Zabow, Stephen Dodd, Alan Koretsky, John Moreland
  • Patent number: 10188658
    Abstract: Described are methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimized pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: January 29, 2019
    Assignee: WisTa Laboratories Ltd.
    Inventors: Claude Michel Wischik, Damon Jude Wischik, John Mervyn David Storey, Charles Robert Harrington
  • Patent number: 10188754
    Abstract: Compositions and methods for chemical exchange saturation transfer (CEST) based magnetic resonance imaging (MRI) or frequency labeled exchange (FLEX) imaging are disclosed. Beta-hydroxycarboxylate and beta-aminocarboxylate derivatives including salicylic acid, salicylates, salicylic acid prodrugs, N-alkyl/aryl/acyl/sulfonyl-anthranilic acid analogs, and any aromatic compound with OH/NH group ortho to the carboxylic acid group are disclosed. Such compounds can be used as general MRI organic contrast agents and produce significantly improved contrast in MR images detectable through CEST or FLEX.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: January 29, 2019
    Assignee: The Johns Hopkins University
    Inventors: Xing Yang, Xiaolei Song, Sangeeta Ray, Martin G. Pomper, Michael T. McMahon
  • Patent number: 10183019
    Abstract: Provided herein are methods for treating or preventing glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: January 22, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Heather Raymon, Kristen Mae Hege
  • Patent number: 10183081
    Abstract: The method for remote, non-invasive in vivo control of the activation of light-sensitive bioactive molecules for the purpose of research or therapy is based on delivering to the required site of the body of nanoparticles along with said light-sensitive bioactive molecules. Nanoparticles' core is made from scintillator material that absorbs X-ray and in response emits visible light; they have biocompatible protective coating and surface targeting agents enabling accumulation at the required site(s) within the body. Irradiation of the site with the highly penetrable X-rays causes nanoparticles to emit visible light which will activate light-sensitive bioactive molecule(s) within this site inducing sought therapeutic effect.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: January 22, 2019
    Inventor: Yaroslav M. Shuba
  • Patent number: 10183082
    Abstract: 18F labeled IDO1 imaging constructs are constructed for positron emission tomography (PET). Synthetic methodology involves the coupling of a 1-fluoro-2-halo-4-aminobenzene and a 4-mino-N-hydroxy-1,2,5-oxadiazole-3-carboximidoyl chloride wherein at least one of the coupled compounds comprises an 18F. The 18F labeled IDO1 imaging constructs are useful for imaging cancer cells in a patient.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: January 22, 2019
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Haibin Tian, Robert J. Gillies
  • Patent number: 10179178
    Abstract: Provided is a nanoparticulate composite with two layers. One of the layers comprises one or more metals, which are a paramagnetic metal, a ferromagnetic metal, or a superparamagnetic metal. This layer also contains one or more suitable dopants. The other layer comprises one or more metals of gadolinium, manganese (II), and iron (III), in the form of an oxide or a fluoride. This layer may contain one or more lanthanide dopants. The nanoparticulate composite may be used as a contrast agent, in particular in magnetic resonance imaging.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: January 15, 2019
    Assignee: NANYANG TECHNOLOGY UNIVERSITY
    Inventors: Thatt Yang Timothy Tan, Yan Zhang
  • Patent number: 10179177
    Abstract: The invention provides novel biocompatible upconversion nanoparticle (UCNP) that comprises a core of cubic nanocrystals (e.g., comprising ?-Na Lna, Lnb Lnc F4) and an epitaxial shell (e.g., formed from CaF2; wherein Lnb is Yb), and related methods of preparation and uses thereof.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: January 15, 2019
    Assignee: University of Massachusetts
    Inventors: Gang Han, Jie Shen
  • Patent number: 10172965
    Abstract: This invention relates to radioactive, bone-seeking, pharmaceutical methods, compositions and formulations that have a lower impurity profile, a longer shelf life, improved availability and are less expensive to prepare. The compositions of this invention can be conveniently prepared in a timely manner resulting in improved availability and delivery of the drugs to patients.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: January 8, 2019
    Assignee: IGL Pharma, Inc.
    Inventors: Jaime Simon, R. Keith Frank, David A. Wilson
  • Patent number: 10172966
    Abstract: Disclosed herein are methods, processes, devices, and compositions for the treatment of target cells and/or tissues, the treatment comprising identifying the target cell with positron emission tomography and then directing a epithermal neutron toward the identified target cell. In various aspects, the target cells and/or tissues take up and metabolize boronated glucose and radioactive fluorinated glucose molecules.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: January 8, 2019
    Inventor: Charles Blaha
  • Patent number: 10172959
    Abstract: A delivery system for active agents, and methods of making and using the systems, are provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: January 8, 2019
    Inventor: Mamoun M Alhamadsheh